OncoMatch

OncoMatch/Clinical Trials/NCT06891560

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

Is NCT06891560 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Enfortumab Vedotin for adenoid cystic carcinoma.

Phase 2RecruitingMemorial Sloan Kettering Cancer CenterNCT06891560Data as of May 2026

Treatment: Enfortumab VedotinThe purpose of this study is to find out whether enfortumab vedotin is an effective and safe treatment for people with adenoid cystic carcinoma (ACC).

Check if I qualify

Extracted eligibility criteria

Cancer type

Head and Neck Squamous Cell Carcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Cannot have received: systemic anti-cancer therapy

Lab requirements

Blood counts

Neutrophils ≥ 1500/μL; Platelets ≥ 100x10^3/μL; Hemoglobin > 9.0 g/dL (without pRBC transfusion within the last 2 weeks)

Kidney function

Serum creatinine ≤ 1.5 x ULN OR creatinine clearance (CrCl) ≥ 40 mL/min per Cockcroft-Gault formula

Liver function

AST and ALT ≤ 2.5 x ULN (if liver metastases are present, AST and ALT ≤ 5x ULN); Total Bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ ULN for participants with total bilirubin levels >1.5 x ULN (except participants with Gilbert Syndrome, who can have a total bilirubin < 3.0 mg/dL)

Screening laboratory values must meet the following criteria: Neutrophils ≥ 1500/μL; Platelets ≥ 100x10^3/μL; Hemoglobin > 9.0 g/dL (without packed red blood cell (pRBC) transfusion within the last 2 weeks); AST and ALT ≤ 2.5 x ULN (if liver metastases are present, AST and ALT ≤ 5x ULN); Total Bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ ULN for participants with total bilirubin levels >1.5 x ULN (except participants with Gilbert Syndrome, who can have a total bilirubin < 3.0 mg/dL); Serum creatinine ≤ 1.5 x ULN OR creatinine clearance (CrCl) ≥ 40 mL/min per the Cockcroft-Gault formula if creatinine is >1.5 x ULN

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) · Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) · Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (All Protocol Activities) · Montvale, New Jersey
  • Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities) · Commack, New York
  • Memorial Sloan Kettering Westchester (All Protocol Activities) · Harrison, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify